D2B3is a pre-clinical biotechnology startup dedicated to creating innovative drug delivery technologies for the brain.
D2B3 has raised $500K in total funding. The most recent round was Pre-Seed. The last funding was announced in April 2025.
D2B3's investors include Mission BioCapital.
D2B3 is headquartered in New Haven, United States.
D2B3is a pre-clinical biotechnology startup dedicated to creating innovative drug delivery technologies for the brain.
D2B3 is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"D2B3 — Funding & Investors." VCBacked, April 7, 2025, https://www.vcbacked.co/company/d2b3. Accessed August 1, 2026.
VCBacked. (2025). D2B3 — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/d2b3
{{cite web |title=D2B3 — Funding & Investors |url=https://www.vcbacked.co/company/d2b3 |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated